Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations

NCT05871970 is registered in ClinicalTrials.gov with Protara Therapeutics as lead sponsor.

NCT NCT05871970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05871970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations
Lead sponsor
Protara Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
October 18, 2023
Completion date
May 31, 2027
Enrollment
38 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphatic malformation